Literature DB >> 22144439

Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis.

Songtao Zhao1, Dongxia Zhang, Ling Li, Qing Mao.   

Abstract

We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the Leishmania species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22144439      PMCID: PMC3225147          DOI: 10.4269/ajtmh.2011.11-0449

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study.

Authors:  C P Thakur
Journal:  Int J Antimicrob Agents       Date:  2001-01       Impact factor: 5.283

2.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

3.  Education is key to controlling visceral leishmaniasis.

Authors:  Robert Killick-Kendrick
Journal:  Bull World Health Organ       Date:  2010-01       Impact factor: 9.408

4.  Liposomal amphotericin B for the treatment of visceral leishmaniasis.

Authors:  Caryn Bern; Jill Adler-Moore; Juan Berenguer; Marleen Boelaert; Margriet den Boer; Robert N Davidson; Concepcion Figueras; Luigi Gradoni; Dimitris A Kafetzis; Koert Ritmeijer; Eric Rosenthal; Catherine Royce; Rosario Russo; Shyam Sundar; Jorge Alvar
Journal:  Clin Infect Dis       Date:  2006-08-28       Impact factor: 9.079

5.  Single-dose liposomal amphotericin B for visceral leishmaniasis in India.

Authors:  Shyam Sundar; Jaya Chakravarty; Dipti Agarwal; Madhukar Rai; Henry W Murray
Journal:  N Engl J Med       Date:  2010-02-11       Impact factor: 91.245

6.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.

Authors:  Shyam Sundar; Prabhat Kumar Sinha; Madhukar Rai; Deepak Kumar Verma; Kumar Nawin; Shanawwaj Alam; Jaya Chakravarty; Michel Vaillant; Neena Verma; Krishna Pandey; Poonam Kumari; Chandra Shekhar Lal; Rakesh Arora; Bhawna Sharma; Sally Ellis; Nathalie Strub-Wourgaft; Manica Balasegaram; Piero Olliaro; Pradeep Das; Farrokh Modabber
Journal:  Lancet       Date:  2011-01-20       Impact factor: 79.321

Review 7.  Current diagnosis and treatment of visceral leishmaniasis.

Authors:  Smriti Mondal; Pradyot Bhattacharya; Nahid Ali
Journal:  Expert Rev Anti Infect Ther       Date:  2010-08       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.